Dani Bancroft, Author at Labiotech.eu

About

Former Editor, now flitting back and forth as a freelancer. Originally from London and studied Zoology at the University of Reading, UK. Previous work includes having written for The Spark University Newspaper and the Wellcome Trust.

Articles by Dani Bancroft

News and Trends 21 Sep 2015

Shire’s Adderall alternative granted EMA approval for EU

Intuniv, Shire‘s new anti-stimulatory product for children with attention-deficit hyperactivity disorder (ADHD) between 6-17 years old, is set to hit shelves in Europe following successful market approval by the European medicine agency (EMA). Shire, a pharma giant with a €23.5Bn market cap, dominates the ADHD market. Originally from Basingstoke (England), they also have bases in the […]

September 21, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Sep 2015

Swiss Biotech Boom: Life sciences startups dominate top 100 awards

Exciting news for the Swiss biotech frontline! The TOP 100 Start-Up award is hosted by Startup.ch the Swiss start-up platform (through IFJ Institut für Jungunternehmen) in collaboration with the major paper Handelszeitung and PME Magazine, ranking the 100 most promising new start up companies. Of these 100, a whopping 68 of these start-ups are in the […]

September 19, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

France’s leading Female Bio-entrepreneur joins board of Abivax

Dominique Costantini is one of France’s leading biotech figures, with over 20 years experience on boards, partnerships and business backing in some of the biotech industries leading brands. With a medical background specializing in immunology (from Paris V University), Costantini co-founded oncology focused Onxeo in 1997. Formerly known as BioAlliance Pharma, this biotech went public […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

Californian Amgen has announced its plans to acquire the Dutch pharma Dezima off of Forbion for €265M upfront. An additional €1.1Bn will be paid through development on their cardiovascular drug candidate which has shown good results in its phase II trial. Amgen is set to buy out Forbion’s portfolio of Amsterdam based Dezima Pharma, a […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

This new Bioplastic plant integrates breakthrough Biotech innovations

Bioplastics hasn’t replaced plastics yet. One new milestone has now been reached, the French company Carbios has just opened its pilot plant to produce biodegradable plastics thanks to its breakthrough enzyme-based technology. Whilst various green initiatives push for better regulation of recycling (a prime example being in Berlin!), in reality only around 10% of plastic […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

Welcome to the Golden age for Gene Editing!

Nuclease-based gene editing technology has opened up how biotechs approach genomic research in industry. A review by Boston Consulting Group explores the background to this excitingly complex field, highlighting how the lengthy genetic revolution has been leading up to this point. Boston Consulting Group has released a report on the importance of gene editing to […]

September 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 15 Sep 2015

Will bacteriophages solve the antibiotic resistance problem in the EU?

French Pherecydes Pharma has launched the first EU clinical bacteriophage phase I/II trial to fight hospital acquired infections (HAIs) in military hospitals and burn units. In collaboration with two other French biotechs, the Phagoburn project aims to combat the stigma against human bacteriophage therapies in the EU and US in order to battle the oncoming […]

September 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

ZS Pharma shares shot up by 30% in value this week due to Swiss big-pharma Actelion admitting it might be interested in buying out the biotech for €2.2BN. This comes as ZS Pharma’s hyperkalemia candidate is set to receive FDA approval for May 2016, although this acquisition rumour could be premature given competitor Relypsa is […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

64 million infected: A brief overview of ReViral and its RSV vaccine competition

Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a vaccine. ReViral (London, UK) has secured €18.5M series A investment into its pre-clinical pipeline. VC investors Edmond de Rothschild, OrbiMed and Brace Pharma Capital back this award winning antiviral program, despite an array of competitors. ReViral have got the go […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Breast-milk therapy for Microbiome disease makes BioGaia smile

BioGaia is a leading microbiome biotech from Stockholm (Sweden) who use the beneficial bacterium Lactobacillus reuteri to produce probiotic consumables. The biotech is currently investing millions in another Stockholm biotech, Infant Bacterial Therapeutics (IBT). IBT is developing a therapy for Necrotising enterocolitis (NEC) derived from L.reuteri, which is found in human breast-milk. BioGaia is a […]

September 11, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Dani Bancroft

About

Articles by Dani Bancroft

Shire’s Adderall alternative granted EMA approval for EU

Swiss Biotech Boom: Life sciences startups dominate top 100 awards

France’s leading Female Bio-entrepreneur joins board of Abivax

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

This new Bioplastic plant integrates breakthrough Biotech innovations

Welcome to the Golden age for Gene Editing!

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Will bacteriophages solve the antibiotic resistance problem in the EU?

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

64 million infected: A brief overview of ReViral and its RSV vaccine competition

Breast-milk therapy for Microbiome disease makes BioGaia smile

Subscribe to our newsletter to get the latest biotech news!